#82. Same Target, Different Weapon

Same target, different weapon: why the delivery mechanism changes who a drug helps, and what AI design can predict about which modality fits which target. Produced by Dr. Jake Chen.

AI agents that read papers, run code, and steer experiments are moving from tools toward collaborators. This episode asks who really decides the next research step — the model, a fixed script, or the scientist — and what evidence would prove an agent actually plans rather than merely follows a script. It walks through an autonomy ladder, two landmark agent systems, and a practical pilot framework for drug developers deciding when to trust an agent with real work. Produced by Dr. Jake Chen.

Three fresh stories, one question: what happens when AI stops being a chatbot and starts doing the work of a lab? A swarm of AI agents reads millions of brain cells in minutes and surfaces a new hypothesis for neurodegeneration. A robotics startup bets that machines can learn a chemist's hands. And a pharma giant gives its scientists an AI research partner. We walk through what each story actually shows — and the long road from a half-hour hypothesis to a drug. Produced by Dr. Jake Chen.

Three fresh stories, one question: what happens when AI stops needing a protein's 3D shape and starts working with biology as it actually behaves? A virtual cell trained on proteins rather than genes predicts how cancer cells respond to drugs hour by hour. A new structure-free model finds drug binding sites on disordered proteins that no structure-based method can touch. And the first drug with both an AI-identified target and an AI-designed molecule has dosed its first Phase III patient. We walk through what each result actually shows, and what it doesn't. Produced by Dr. Jake Chen.

AI can now generate millions of molecules, thousands of drug targets, and entire scientific manuscripts in hours — but our capacity to validate any of it hasn't kept pace. This episode walks through the trust crisis in AI drug discovery: from ultra-large virtual screening libraries to AI-generated papers arriving faster than peer review can handle, from citation errors in machine-written manuscripts to the clinical programs that give real reason for optimism. The central question is no longer whether AI can generate drug candidates, but whether it can reliably improve therapeutic decisions — and why trustworthy evidence must become the industry's most valuable asset. Produced by Dr. Jake Chen.

Biohub's Virtual Biology Initiative just expanded to $1.8 billion — backed by the DOE, NIH, Google DeepMind, Isomorphic Labs, and Meta — to build the data foundations for predictive AI in biology. But a new perspective argues the field is celebrating too early: today's biological data are sparse across the spatial, temporal, and causal dimensions that actually determine how cells respond to drugs. This episode walks through why virtual cells are not digital twins, where the models could genuinely accelerate drug discovery first, and the validation ladder that separates credible prediction from hype. Produced by Dr. Jake Chen.

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr. Jake Chen.

In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence suggests that these firms are becoming significantly more productive at generating patentable molecules, yet they have not demonstrated the same advantage in discovering entirely new biological targets. Companies such as Insilico Medicine and Genesis show clear strengths in chemical optimization and development speed, while insitro emphasizes causal biology, human genetics, and disease-relevant data. We explore why AI currently appears better at reducing chemical and search risks than overcoming the biological failures that frequently derail late-stage clinical trials. Ultimately, the most promising model may be an integrated pharmaceutical operating system that combines proprietary experimental data, automated discovery, and clinical development. Produced by Dr. Jake Chen.

In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physical lab instruments creates critical security risks. These range from immediate hazards—such as cyber-physical vulnerabilities, sequence-screening evasion, and flawed objective optimization—to systemic risks from unaligned superintelligence and uncontrolled biological synthesis. Mitigating these threats requires a capability-based preparedness framework featuring model-independent hardware interlocks, strict permission boundaries, and mandatory physical controls over automated synthesis. Produced by Dr. Jake Chen.

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind this molecular trap to emerging clinical promise in pancreatic and other KRAS-driven cancers, the daraxonrasib FDA approval reveals a potential turning point in precision oncology—while examining resistance, patient selection, and what KRAS teaches us about drugging the seemingly impossible. Produced by Dr. Jake Chen.